Searched for
WYETH PHARMA
Wyeth Ltd's Q1 net profit up 28% at Rs 28.46 croreThe company had posted net profit of Rs 22.18 crore for the corresponding period of the previous financial year, Wyeth said in a filing to ...- Pfizer rallies 18% intraday, closes day 9% higher on parent's restructuring bidThe company said that a unit of its parent Pfizer Inc will buy about 61 per cent stake from two other units after an internal restructuring.
- Pfizer-Wyeth merger good for shareholders: Ranjit Kapadia, Centrum BrokingIn an interview with ET Now, Ranjit Kapadia, Sr VP-Pharma, Centrum Broking Ltd, shares his views on the Pfizer-Wyeth merger.
- Wyeth surges 20%; hits upper limit on merger plans with PfizerShares of Wyeth zoomed by 20 per cent to hit the upper circuit limit after the company announced its plan to merge with Pfizer.
- Pfizer, Wyeth board meet on Nov 23 to discuss merger plansPfizer India today said the respective Boards of Directors of Pfizer Ltd and Wyeth Ltd will meet on November 23 to consider the merger prop...
- Wyeth Q2 net down 11 pc at Rs 30.25 croreWyeth Ltd a subsidiary of global pharma major Pfizer Inc today said its net profit declined by 10.89 per cent to Rs 30.25 crore for the qua...
- Extremely bullish on MNC pharma space: Angel BrokingOpportunity in the pharma industry is huge so probably these parent companies may get more serious because they have been so far not taking...
- Sun Pharma shares plunge on damages sought by WyethShares of Sun Pharmaceutical dropped nearly 3% as the company said that US-based Wyeth has sought damages worth $960 mn in a patent dispute.
- Wyeth makes $960 mn claims on Protonix patent case: Sun PharmaSun Pharma said US-based Wyeth Pharma has sought damages worth $960 mn related to their ongoing patent dispute over generic version of Prot...
- Dr Reddy's reach settlement with Wyeth over EffexorDr Reddy's Laboratories has reached a deal with Wyeth LLC over a patent litigation involving generic version of blockbuster anti-depressant...
- Wyeth looks strong in the pharma space: Ganesh ShanbhagET Now spoke to Ganesh Shanbhag of SMS Financial Services on his stock picks.
- Pfizer’s growth outlook seen strongThe Pfizer stock has offered better returns to investors than the Bombay Stock Exchange’s (BSE) benchmark index, the Sensex, over the past ...
- Sun gets a boost as FDA rejects rival Osmotica’s pleaSun Pharmaceutical Industries’ plan to launch a copy of US-based Wyeth’s blockbuster anti-depressant capsule Effexor XR got a big boost aft...
- Wyeth to boost Pfizer's share in Indian marketPfizer's $68-billion buyout of Wyeth may help catapult its local subsidiary into the top ten league of Indian drugmakers.
- Sun Pharma launches generic Protonix tabletsSun Pharmaceutical Industries Ltd on Wednesday commercially launched generic Pantoprazole Sodium Delayed Release tablets, 40 mg, which is A...
- Teva’s protonix version sale in US to hit SunIn a development which may impact Sun Pharma’s hopes of a windfall by selling generic versions of Wyeth’s $2.5-billion drug Protonix.
- Wyeth's 'nod' to Sun generic may be tacticalWyeth’s decision to issue a covenant ‘not-to-sue’ (CNS) to Sun Pharmaceutical Industries for seeking approval to sell its version of anti-d...
- Wyeth not to sue Sun Pharma over generic VenlafaxineSun Pharmaceutical Industries has received a covenant ‘not to sue’ from Wyeth over Sun Pharma’s abbreviated new drug application for generi...
- 3 cos sue Wyeth over Zosyn patentThree generic pharmaceutical companies, including one from India, have taken legal action against US pharma major Wyeth.
- Wyeth sells Forhans brand to John Oak RemediesWyeth Ltd on Wednesday said it has sold the Forhans brand of toothpaste and toothpowder to John Oak Remedies Private Ltd for Rs 2.25 crore.
Load More
